Administered bi-monthly, the new PrEP injection CAB-LA is more effective than oral treatments, the authors state.
Yet, the article outlines, the drug is currently unavailable in countries where HIV is most prevalant.
"Even in a high-income country such as the US, modelling studies have shown that the potential public health benefit of CAB-LA is jeopardised by its cost," the authors note.
The article draws on the Foundation's 2021 Access to Medicine Index to argue that a lack of access to essential medicines is more widespread. "The 2021 [Access to Medicine Index] found that only eight companies implemented ways to make it easier to get medicine. In poorer countries, less than half of the most needed medicines were available."